A
Alcista
Alcista · 25%CRIS
$2.47
Precio del escenario
$0.714
+0.057 (+8.00%)Al cierre
Loading chart…
- Máximo
- 1.500
- Apertura
- 0.720
- Precio medio ponderado por volumen
- 0.94
- Volumen
- 51.14M
- Capitalización
- 43.91M
- Mínimo
- 0.620
- Importe
- 48.31M
- EV/EBITDA, TTM
- 0.04
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Análisis de IA of Curis Inc (CRIS)
ComprarCuris Inc appears to be a good buy right now due to its recent price surge of 75.19% over the last five days, indicating strong momentum. The RSI is at 80.385, suggesting it is in overbought territory but also reflects strong buying interest. The forward P/E ratio is currently at 0, which indicates potential for future earnings growth as the company progresses with its clinical trials. However, a significant risk is the net loss of $24.2 million reported for Q1 2026, which highlights ongoing financial challenges that could impact investor sentiment.
Recomendaciones de analistas (4)
+1440.83% de potencial alcista
Comprar
4 Comprar
0 Mantener
0 Vender
Actual: 0.71
Mínimo
5.00
Promedio
11.00
Máximo
17.00
H.C. Wainwright
Comprar
$43
2026-07-24
H.C. Wainwright
2026-07-24
Precio objetivo
$43
Comprar
Evercore ISI
Superar al mercado
$38
2026-01-05
Evercore ISI
2026-01-05
Precio objetivo
$38
Superar al mercado
Canaccord
Mantener
$30
2025-12-22
Canaccord
2025-12-22
Precio objetivo
$30
Mantener
BofA
Comprar
$35
2025-12-15
BofA
2025-12-15
Precio objetivo
$35
Comprar
Canaccord
Mantener
$28
2025-12-02
Canaccord
2025-12-02
Precio objetivo
$28
Mantener
Métricas de valoración
El PER previsto actual de Curis Inc (CRIS) es 0.00, frente a su media de 5 años de -1.88.
Escenarios de precio de Alphio AI para CRIS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.007-30PRnewswireCuris Achieves Key Milestone in CLL Study with Emavusertib
9.007-22PRnewswireCuris Updates Clinical Data in PCNSL and Increases Guidance for CLL
2.007-06NewsfilterCuris Announces Key Enrollment Milestone in TakeAim CLL Study
8.507-06PRnewswireCuris Achieves Key Milestone in TakeAim CLL Study
- 2.006-26Newsfilter
Curis Initiates CLL Study and Confirms Shareholder Vote Results
Preguntas frecuentes sobre CRIS, respondidas por Alphio AI
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Curis Inc appears to be a good buy right now due to its recent price surge of 75.19% over the last five days, indicating strong momentum. The RSI is at 80.385, suggesting it is in overbought territory but also reflects strong buying interest. The forward P/E ratio is currently at 0, which indicates potential for future earnings growth as the company progresses with its clinical trials. However, a significant risk is the net loss of $24.2 million reported for Q1 2026, which highlights ongoing financial challenges that could impact investor sentiment.
4 analysts cover CRIS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- Oil Prices Surge Above $105 Amid US-Iran Conflict: Energy Investment Opportunities in November 2026Oil prices climb past $105 as US strikes Iran's Qeshm Island. Discover energy investment opportunities, top oil stocks, and market outlook for November 2026.
- Oil Prices Surge Above $105 Amid US-Iran Conflict: Energy Investment Opportunities in November 2026Oil prices climb past $105 as US strikes Iran's Qeshm Island. Discover energy investment opportunities, top oil stocks, and market outlook for November 2026.
- 2026 Midterm Results Are In: What Democratic Control of Congress Means for the Stock MarketDemocrats win House and Senate in 2026 midterms: what divided government under Trump means for stocks, sectors, volatility, and investor checklists.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.